Citations

Clear

4439 citation(s) found for "Lee, E".

Comparative Outcomes of Direct Oral Anticoagulants Versus Aspirin After Ventricular Tachycardia Ablation
Yeo, Yong Hao , Koo, Thai Hau, Sorajja, Dan , El‐Masry, Hicham, Santangeli, Pasquale , Higuchi, Koji , Sroubek, Jakub , Lee, Justin Z. , Tan, Min Choon , Sorajja, Dan , El-Masry, Hicham, Santangeli, Pasquale , Higuchi, Koji , Sroubek, Jakub , Deshmukh, Abhishek J , Yeo, Yong Hao , Masry, Hicham El

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjqcco/qcag132 | PMID 42622624 Get It

A National Delphi Study to Inform Modernization of Anesthesiology Residency Case Log Requirements
Saddawi‐Konefka, Daniel , Kacmar, Rachel M. , Long, Timothy R. , Mitchell, John , Ang, Lee, Ambardekar, Aditee P. , Mitchell, John D , Ang, Lee Yi

Mayo Clinic

Anesthesiology | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/aln.0000000000006337 | PMID 42610591 Get It

Background: The Accreditation Council for Graduate Medical Education (ACGME) case log system establishes minimum clinical experiences for anesthesiology residency. While core program requirements were last updated in 2016, case log minimums themselves have not undergone a major revision in approximately two decades. Consequently, current requirements may not fully reflect changes in anesthetic practice and the evolving scope of perioperative medicine. In anticipation of major ACGME revisions in 2027, this study aimed to develop consensus-driven recommendations for modernizing residency case logs. Methods: A three-round modified Delphi study was conducted with a nationally representative panel of 60 stakeholders, including anesthesiology residency program directors and academic and private practice anesthesiologists. Panelists evaluated a comprehensive list of potential case categories across three domains: technical skills, surgical case characteristics, and patient demographics. In Round 1, panelists proposed minimum numbers or suggested that no requirement was necessary. Rounds 2 and 3 utilized iterative feedback to determine consensus on the necessity of requirements and specific minimum thresholds. Consensus was defined as at least two-thirds agreement. Results: Sixty invited experts completed all three rounds (100% response rate). The panel reached consensus to recommend new minimum requirements across several areas not currently tracked with minimums, including arterial lines (40), central lines (20), fiberoptic intubation (10), one-lung ventilation (10), neuromonitoring (10), POCUS (10 Cardiac, 10 Lung), and NORA (20 cases). Regarding existing requirements, consensus was reached to recommend increasing total peripheral nerve blocks from 40 to 60, with added requirements for anatomic specificity, and cardiac case minimums from 20 to 25. The panel also established consensus definitions for life-threatening pathologies to standardize reporting. The panel did not achieve consensus on several areas, including, for example, whether a minimum requirement for patients younger than 3 months should be maintained. Conclusion: These findings provide stakeholder-validated recommendations to inform upcoming ACGME requirement revisions.
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
NSQIP Outcomes for Open and Minimally Invasive Gastrectomy for Malignancy
Lee, Frank G. , Cross, Ashton E. , Habermann, Elizabeth B. , Thiels, Cornelius A. , Grotz, Travis E. , Hanson, Kristine , Cross, Ashton E , Habermann, Elizabeth , Thiels, Cornelius A , Grotz, Travis E , Hanson, Kristine T. , Lee, Frank G

Mayo Clinic

Journal of Surgical Oncology | August 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jso.70359 | PMID 42604579 Get It

ABSTRACT Background ACS‐NSQIP began capturing operative approach in 2022. With increased adoption of minimally invasive (MIS) techniques for malignancy, a contemporary review of benchmark outcomes for open, laparoscopic and robotic gastrectomy is warranted. Methods We performed a retrospective cohort study of adults in ACS‐NSQIP (2022–2024) undergoing partial or total gastrectomy (CPT 43631‐4 and 43620‐2) for cancer. Outcomes included operative time, length of stay (LOS), unplanned conversion‐to‐open, and 30‐day morbidity, mortality, and readmission. Multivariable logistic regression evaluated patient and operative factors associated with morbidity. Results Among 1,459 patients (median age 66, 60.4% male), 66.8% underwent partial gastrectomy and 33.2% total gastrectomy. Approaches were 61.2% open, 19.5% laparoscopic, and 19.3% robotic. Thirty‐day mortality (1.8%), major complications (18.2%), and readmissions (10.3%) did not differ by approach. Unplanned conversion‐to‐open occurred in 14.0% of MIS. Robotic had longer median operative time of +1.2 and +1.7 h than laparoscopic and open and median −1 and −2 days shorter LOS respectively ( p < 0.001). Hypoalbuminemia (OR 3.10), CKD ≥ 3 (OR 1.75), and anemia (OR 1.48) were independently associated with major complications ( p < 0.05). Conclusion Operative approach influences operative time and LOS but not short‐term morbidity and mortality. The newly available ACS‐NSQIP operative approach variable enables approach‐specific benchmarks for cancer‐related gastrectomy.
Management of Recurrent Atrial Fibrillation After Catheter Ablation: Five-Year Outcomes of Repeat Catheter Ablation Versus Antiarrhythmic Therapy
Yeo, Yong Hao, Wong, Helen, Vignarajah, Aravinthan , Tan, Min Choon , Vigneswaramoorthy, Nishanthi , Lee, Justin, Scott, Luis, Tamirisa, Kamala P. , Sorajja, Dan , DeSimone, Christopher, Yeo, Yong Hao , Yeo, Yong Hao , Wong, Hermon Kha Kin , Deshmukh, Abhishek J , Scott, Luis R , Tan, Min C , Lee, Justin Z. , DeSimone, Christopher V.

Mayo Clinic

Europace | August 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/europace/euag215 | PMID 42605195 Get It

Abstract Background Recurrence of symptomatic atrial fibrillation (AF) after catheter ablation (CA) is not uncommon. However, real-world long-term data on clinical outcomes of rhythm control strategies in patients with recurrent AF after CA remain limited. Methods Using the TriNetX database, we identified adult patients (≥18 years) with recurrent AF after index CA. A 3-month blanking period was applied, during which no rhythm-control therapy was received. Patients were classified into two groups: repeat CA or initiation of antiarrhythmic drug (AAD) therapy. Propensity score matching (PSM) was performed to balance baseline characteristics. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Outcomes included all-cause mortality, all-cause hospitalization, heart failure (HF) exacerbation, ischemic stroke, and major bleeding over 5 years. Results Among 4,056 patients with recurrent AF post-CA, 17.2% underwent repeat CA. After PSM, 697 patients in the repeat CA group (mean age 68.9 ± 9.6 years; 35.7% female) and 697 in the AAD group (mean age 68.4 ± 10.0 years; 37.6% female) were analyzed. Repeat CA was associated with lower all-cause mortality (3.3% vs 8.2%; HR 0.44; 95% CI, 0.27–0.72; P &lt; 0.01), all-cause hospitalization (42.8% vs 56.4%; HR 0.71; 95% CI, 0.61–0.82; P &lt; 0.01) and HF exacerbation (12.5% vs 24.8%; HR 0.50; 95% CI, 0.39–0.64; P &lt; 0.01). No differences were observed in ischemic stroke (5.3% vs 4.7%; HR 1.22; 95% CI, 0.77–1.96; P = 0.40) or major bleeding (4.6% vs 6.2%; HR 0.82; 95% CI, 0.52–1.29; P = 0.39). Conclusions Repeat CA was associated with lower mortality, hospitalization, and HF exacerbation over 5 years.
Spatial Logic Reconciles Gene-signature Methods in Triple Negative Breast Cancer
Bastian, William C, Lee, Ji‐Hoon , Griffiths, Lyra Maria, Aiello, Meili, Buchwald, Zachary Scott, Thompson, E. Aubrey, Li, Zaibo , Li, Xiaoxian , Meisel, Jane Lowe , Shaker, Nada , Griffiths, Lyra M., Buchwald, Zachary S. , Liu, Yi , Thompson, E. Aubrey , Douglass, Eugene

Mayo Clinic

No container title available | August 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.13.744259 | PMID 42845422 Get It

Abstract Triple-Negative Breast Cancer (TNBC) presents a significant clinical challenge due to its heterogeneity and lack of targeted treatment options, with chemotherapy and immunotherapy combinations currently serving as the main therapeutic strategy. Efforts to address TNBC heterogeneity have largely focused on classifying intrinsic cancer subtypes based on differential tumor mRNA expression, a strategy that has proven effective in hormone receptor-positive breast cancers but has yet to yield a clinically useful predictor of survival or treatment response in TNBC. We hypothesize that both the intrinsic characteristics of TNBC and the surrounding immune microenvironment influence treatment outcomes and that immune cell infiltration affects TNBC subtype classification and response variability. To explore this hypothesis, we compared the predictive and prognostic capabilities of cancer subtype-based (TNBC-type) gene signatures and immune cell deconvolution methods (CIBERSORT) within the same TNBC datasets. We found that immune cell abundance outperformed TNBC subtype-signatures and multicellular immune cell aggregates showed the highest performance of all. More specifically, aggregate immune cells associated with tertiary lymphoid structures and tumor associated macrophages/monocytes demonstrated statistically significant predictive value. These findings were confirmed in an independent cohort of 67 TNBC patients treated with neoadjuvant chemotherapy. Further, single-cell RNA sequencing analysis revealed that the predictive power of cancer-subtype could be partially explained by immune- and stromal features. Examination of single-cell resolution spatial transcriptomic data confirmed presence of TLS-like, TAM- and cancer-stromal niches within TNBC biopsy samples that were associated with treatment response. Overall, our results highlight that immune cell aggregates, which capture the spatial organization of the TME, outperform cell-type specific gene signatures in predicting TNBC outcomes. Our novel approach provides a robust framework for interpreting spatial relationships in bulk RNA-seq data, offering a pathway for reconciling past data with current advancements in spatial profiling technologies. This work paves the way for future studies to leverage the multi-cellular complexity of TNBC, enhancing diagnostic precision and facilitating the development of therapies that strategically modulate the tumor microenvironment for improved anti-cancer responses.
Selection of Breast Biopsy Markers: Effect on Breast Imaging Procedures, Follow-up, and Costs
Moseley, Tanya W. , Adrada, Beatriz E. , Arribas, Elsa , Hesley, Gina , Whitman, Gary J. , Rauch, Ronald A., Guirguis, Mary S. , Kapoor, Megha , Lee, Christine U. , Hesley, Gina K. , Arribas, Elsa M , Urban, Matthew W , Whitman, Gary J , Rauch, Ronald A , Guirguis, Mary S , Kapoor, Megha M , Lee, Christine , Adrada, Beatriz E , Urban, Matthew W.

Mayo Clinic

RadioGraphics | August 13, 2026 | Volume: 46 | Issue: 9 | Pages: No page available

10.1148/rg.250151 | PMID 42594023 Get It

Breast biopsy markers have evolved from simple metallic devices to sophisticated multimaterial tools that have become essential for breast cancer care, demonstrating their clinical benefits in surgical planning, radiation targeting, and cost reduction.
Real-World Evidence of Disproportionate Financial Toxicity and Health-Related Social Needs Among Adolescents and Young Adults Receiving Care at an NCI-Designated Cancer Center
Lee, Minji K. , Steinert, Kimberly O., Mason, Jordan A., Hanson, Wendy A., Rosenthal, Allison , Khera, Nandita , Lee, Minji K , Rosenthal, Allison , Kimball, Brittany , Steinert, Kimberly O., Allen‐Rhoades, Wendy , McWilliams, Robert R.

Mayo Clinic

Current Oncology | August 13, 2026 | Volume: 33 | Issue: 8 | Pages: 477

10.3390/curroncol33080477 | PMID 42645382 Get It

Financial toxicity is a significant but often overlooked consequence of cancer for adolescents and young adults (AYAs, 15–39 years old), who face limited savings, unstable employment, and insurance gaps that heighten financial stress. As part of a larger initiative to determine whether our cancer center can use an existing social drivers of health (SDOH) screening process to identify patients who may benefit from targeted supportive interventions, we sought to characterize financial strain, toxicity, and SDOH needs in AYAs treated in our cancer center and compare them to both younger and older cancer patients. This is a cross-sectional observational study at Mayo Clinic of patients with an oncology-related department visit between 8 September 2023–4 June 2024 (N = 81,731) who completed routine institutional electronic screenings for financial strain and SDOH. Survey items assessed financial strain, transportation barriers, and food insecurity; institutional billing data captured financial toxicity (unresolved balances, collection referrals, write-offs). AYAs (n = 5655) were more likely than non-AYAs to report medium/high financial strain, have unpaid debt, or have an unresolved balance, referral to a collection agency, or bad debt write-off, with nearly double the odds of medium/high financial strain compared to patients over 40 (OR 2.02, 95% CI 1.84–2.23, p < 0.001). Within AYAs, ages 26–32 bore the greatest burden: 24.2% in the medium/high-risk category, 9.4% with unresolved billing issues or collections, and 11.6% reporting food insecurity. These findings identify AYAs—particularly those 26–32—as a distinct high-risk group for financial toxicity and health-related social needs, underscoring the need for targeted interventions, tailored financial navigation, and policy efforts to reduce economic barriers to care. Future research should evaluate the effectiveness of these interventions in mitigating financial toxicity, addressing health-related social needs, and improving patient outcomes in this population.
Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A. , Ballman, Karla V. , Mercurio, Ann, Siegelin, Markus D., Tuohy, Kyle , Mansouri, Alireza , Simonelli, Matteo, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Hervey-Jumper, Shawn L., Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter, Neugut, Alfred I. , Iwamoto, Fabio M., Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Brown, Paul D , Vogelbaum, Michael A , Ballman, Karla , Mercurio, Ann , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Dehais, Caroline , Dipasquale, Angelo , Grinband, Jack , Yu, James B , Walch, Henry , Parker, Mitchell I , Shuryak, Igor , Roy, Soumyajit , Gallitto, Matthew , Horowitz, David P , McKhann, Guy M , Bruce, Jeffrey N , Ostrom, Quinn T , Neugut, Alfred I , Pike, Luke R G , Cheng, Simon K , Kachnic, Lisa A , Mehta, Minesh P , Wang, Tony J C , Minniti, Giuseppe , Siegelin, Markus D. , Kocakavuk, Emre , Ducray, François , Simonelli, Matteo , Yu, James B. , Hervey‐Jumper, Shawn L. , McKhann, Guy M. , Canoll, Peter , Ostrom, Quinn T. , Iwamoto, Fabio M., Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Journal of Clinical Oncology | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-01846 | PMID 42585601 Get It

PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.